Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PARALLEL GROUP, SINGLE-DOSE DESIGN TO DETERMINE THE EFFICACY AND SAFETY OF INTRAVENOUS NA-1 IN SUBJECTS WITH ACUTE ISCHEMIC STROKE UNDERGOING ENDOVASCULAR THROMBECTOMY.

Intervention/treatment:
NA-1
Medical condition:
STROKE
Protocol code:
NA-1-007
Control number:
189317
Status:
Closed
Approved:
December 03, 2015
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02930018
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Michael Tymianski, MD PhD
Organization
NoNO Inc.
Phone:
4165831687
Sponsor
NONO INC

Locations

Alberta

University of Alberta Hospital
Edmonton, Alberta, T6G 2B7
University of Calgary - Foothills Medical Centre
Calgary, Alberta, T2N2T9

British Columbia

Vancouver Stroke Program Research Office/ Vancouver General Hosptial
Vancouver, British Columbia, V5Z 1M9

Nova Scotia

Queen Elizabeth II Health Science Centre
Halifax, Nova Scotia, B3H 3A7

Ontario

Hamilton General Hospital
Hamilton, Ontario, L8L 2X2
London Health Sciences Centre- University Hospital
London, Ontario, N6A 5A5
St Michael's Hospital
Toronto, Ontario, M5B 1W8
Sunnybrook Health Centre
Toronto, Ontario, M4N 3M5
The Ottawa Hospital
Ottawa, Ontario, K1Y 4E9
University Health Network - Toronto Western Hospital
Toronto, Ontario, M5T 2S8

Quebec

CHU de Quebec- Universite Laval- Hopital de l'Enfant-Jesus
Québec, Quebec, G1J 1Z4
CHUM Hopital Notre-Dame
Montreal, Quebec, H2L 4M1
Montreal Neurological Institute and Hospital
Montreal, Quebec, H3A1A1

Saskatchewan

Royal University Hospital
Saskatoon, Saskatchewan, S7N 0W8

Results

See the results from the trial NCT02930018. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?